oral glp 1 in development The of an GLP-1 receptor agonist for the management o | DDDT Orforglipron FDA Approval: Why the

These observations lend support to the hypothesis that GLP-1/GLP-1R axis might directly act on ovarian MGCs to promote the follicular development in a dose-dependent manner, likely contributing to the oocyte maturation in PCOS

A role for mineralocorticoid receptor antagonism in DKD has been appealing with a strong physiological rationale, since mineralocorticoid receptors are widely expressed in kidney and cardiac tissue, and their activation by aldosterone leads to hemodynamic and non-hemodynamic effects culminating in inflammation, fibrosis, and progression of cardiac and kidney disease [9097]

The higher doses also bring the possibility of temporary side effect recurrence

Ozempic has proven behavioral changes related to eating such as decreased (or astonishingly zero) cravings for sugary foods and alcohol, and aversions to former favorite comfort foods or guilty pleasures

Patients may require ongoing supportive care and monitoring during this extended period until the medication is cleared from the body

GLP-1R activation has a significant effect on glycemic control in patients with T2DM through a variety of mechanisms, including stimulation of insulin secretion, inhibition of glucagon secretion, protection of -cells from apoptosis, slowing gastric emptying and increasing satiety ( 2 GLP-1R GLP-1R is a G protein-coupled receptor (Wu et al., 2020) (Figure 1A)